Tenofovir disoproxil fumarate monotherapy maintains @entity97 suppression achieved by a "de novo" combination of XXXX - @entity24488 : a pilot study.

@entity1 @entity97 @entity8 @entity16332 @entity24488 @entity409 @entity6194 @entity17705 @entity15833 @entity13211
UNASSIGNED: @entity6194 ( @entity6194 ) treatment aims at long-term suppression of @entity97 replication and improvement in clinical outcomes. We describe the data of a pilot, non-profit study in which @entity1 with @entity6194 were treated with de novo combination @entity16332 - @entity24488 (LAM-ADV) for at least four years with a view to @entity97 suppression and resistance prevention, and shifted to @entity15833 (TDF) when new antiviral agents were available. Fifty-one @entity13211 negative @entity1 were enrolled. Histology was available for 39 @entity1 and data of @entity409 ( @entity409 ) for 24 @entity1 at baseline. Serum quantification of HBsAg and HBVDNA was obtained regularly during the follow-up. In 10 and 7 @entity1 , a paired histology and @entity409 were available at the end of LAM-ADV treatment, respectively. The de novo LAM-ADV combination was able to obtain HBVDNA suppression and ALT normalization in one year in most of the @entity1 and in the second year in the remaining. Histology improved in @entity1 with paired biopsy, but tissue HBsAg was present in all but one @entity1 after 48 months of therapy. TDF maintained biochemical and virological response throughout the follow-up. @entity8 during LAM-ADV therapy improved on shifting to TDF; only in 4 cases was a second shift to @entity17705 needed. TDF was safe and effective in maintaining @entity97 DNA suppression achieved by a long-term course of LAM-ADV de novo combination for the treatment of @entity13211 -negative @entity6194 .
